ROS-activated ABL1 mediates inflammation through regulating NF-<i>κ</i>B1 and STAT3, which subsequently leads to the development of GC and GC-related depression.
In this review, we examine the evidence to illuminate the molecular mechanism of ABL1 in the progression of GC patients with depression and identify out new and effective methods for the initial and long‑term treatment of GC.